Plus Therapeutics, Inc. announced on February 20, 2025, the appointment of Michael Rosol, Ph.D., as its Chief Development Officer. Dr. Rosol will be responsible for leading the company’s clinical, pre-clinical, and biomarker development activities.
Dr. Rosol brings 25 years of experience in clinical trial design, operations, and regulatory execution, including previous roles at Navidea Biopharmaceuticals and Novartis Pharmaceuticals. His background in oncology and radiotherapeutic drug development aligns with Plus Therapeutics' pipeline.
This appointment is considered timely as the company approaches an inflection point in its clinical development, moving from mid-stage to pivotal trials. Dr. Rosol's expertise is expected to be a strong match for the company's clinical pipeline and stage of development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.